View Main Condition: Non-Small Cell Lung Cancer (NSCLC)
Heather Wakelee is an Oncologist in Palo Alto, California. Wakelee has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of EGFR Positive Lung Cancer. She is also highly rated in 17 other conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Hormone Replacement Therapy (HRT), and Tissue Biopsy. Wakelee is currently accepting new patients.
Anne Tsao is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Tsao has been practicing medicine for over 25 years and is rated as an Elite expert by MediFind in the treatment of EGFR Positive Lung Cancer. She is also highly rated in 15 other conditions, according to our data. Her top areas of expertise are Malignant Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Tsao is currently accepting new patients.
Lecia Sequist is a Hematologist Oncology specialist and an Oncologist in Newton, Massachusetts. Sequist has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of EGFR Positive Lung Cancer. She is also highly rated in 11 other conditions, according to our data. Her top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Sequist is currently accepting new patients.
Summary: This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7).
Summary: This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an ...